Thymogen (L-glutamyl-L-tryptophan)
Thymagen, Timogen, Glu-Trp, EW dipeptide, glutamyl-tryptophan
Thymogen is a synthetic dipeptide, Glu-Trp, identified by Russian researchers as an active fragment within the calf thymus extract thymalin. It is a registered medicine in Russia with decades of Soviet-era clinical use, but the supporting literature is small, largely Russian-language and rarely randomised. It is routinely confused with the chemically distinct compound SCV-07, whose trial data do not transfer.
Mechanism
Thymogen is the synthetic dipeptide L-glutamyl-L-tryptophan (Glu-Trp, EW), identified by Khavinson's group as one of the active short-peptide constituents of the calf thymus extract thymalin. Its proposed action is on T-lymphocyte differentiation and maturation, with reported increases in CD3+ and CD4+ populations in immunodeficient states, restoration of CD4/CD8 balance, and effects on interferon and interleukin production. Laboratory work from the same programme also reports B-cell activation in ageing spleen tissue via reduced apoptosis and increased proliferation. As with the wider Khavinson programme, a gene-regulatory mechanism is proposed in which the dipeptide enters cell nuclei and modulates transcription, a model that remains the property of one research school rather than an independently established pathway.
A plausible pharmacological argument for a dipeptide is transport: di- and tripeptides are substrates for the proton-coupled oligopeptide transporters PEPT1 and PEPT2, which would in principle permit absorption of an intact dipeptide across intestinal and nasal epithelium. Khavinson's group has published on POT and LAT carrier-mediated uptake of ultrashort peptides on exactly this basis. What has not been shown is that intact Glu-Trp survives peptidase activity to reach immune cells in vivo at concentrations sufficient to do anything. Free dipeptides are rapidly hydrolysed, and glutamate and tryptophan are both abundant free amino acids, so demonstrating a specific signalling effect distinct from simple amino acid delivery is a real analytical challenge that has not been convincingly met.
One clarification matters more than any of the above. Thymogen must not be confused with golotimod, also known as SCV-07, which is γ-D-glutamyl-L-tryptophan, the same two amino acids joined through the glutamate side-chain carboxyl rather than its alpha-carboxyl, and with D-stereochemistry at the glutamate. That is a different molecule with different metabolic stability and an entirely separate development history. The two are frequently conflated in vendor material and occasionally in review articles. Human trial data generated for SCV-07 do not apply to thymogen.
What the research shows
Thymogen has been a registered medicine in Russia for decades and carries an accumulated Soviet and Russian clinical literature across tuberculosis, inflammatory disease of the female genital tract, type 1 diabetes and perioperative immunodeficiency. Judged by contemporary standards these reports are small, inadequately described, and rarely controlled. Examples indexed in PubMed include work on immunity in destructive pulmonary tuberculosis (Medus, 1999) and immunodeficiency correction in type 1 diabetes (Zhuk, 1996, reporting clinical effect in 94.4% of patients and laboratory improvement in 83.3%, figures with no stated comparator that should not be read as controlled evidence). Both are Russian-language with limited methodological detail available in the international record. Reports on use in inflammatory gynaecological disease also circulate; the specific 1992 Tsvelev citation given in the draft could not be confirmed in PubMed and has been removed rather than asserted.
The study most often cited as rigorous is Smirnov and colleagues (2011), a double-blind randomised placebo-controlled trial of preoperative thymogen (administered intranasally for seven days before surgery) in elderly patients undergoing surgery for abdominal tumours, reporting restoration of cellular immunity parameters, fewer postoperative complications and shorter recovery. The report is Russian-language in a specialist gerontology journal, and the sample size is not stated in the accessible abstract, which makes independent appraisal of the effect size impossible.
The related but chemically distinct compound SCV-07 (golotimod, γ-D-glutamyl-L-tryptophan) was developed in the United States and reached phase 2 in Western trials in chemoradiation-induced oral mucositis and in chronic hepatitis C. The supporting efficacy data were generated in golden Syrian hamster models of radiation- and chemoradiation-induced mucositis (Watkins, 2010). None of these programmes reached approval, and none produced a clearly positive, peer-reviewed phase 2 efficacy result. A companion analysis of 28 head and neck cancer patients attempted to identify gene clusters predicting individual response (Alterovitz, 2011), which is itself an acknowledgement that response was inconsistent. It bears repeating: this is a different molecule, and even taken at face value the SCV-07 programme ended without approval. The specific registry identifiers and enrolment figures for the SCV-07 phase 2 trials given in the draft could not be verified in this audit and have been removed.
No trial of thymogen itself is registered on ClinicalTrials.gov.
Evidence assessment
Limited evidence
Human data exist and it is a registered medicine in Russia, but the clinical literature is small, decades old, overwhelmingly Russian-language, rarely randomised or blinded, and never independently replicated internationally; the single reported randomised trial does not state its sample size in the accessible record, and no trial of thymogen is registered on ClinicalTrials.gov.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
[Application thymogen for preoperative preparation of elderly patients with tumor processes in abdominal cavity] Limited evidence
Reported restoration of structural and functional parameters of cellular immunity, with notably fewer postoperative complications and shorter recovery time than placebo.
Attenuation of radiation- and chemoradiation-induced mucositis using gamma-D-glutamyl-L-tryptophan (SCV-07) Preclinical only
SCV-07 reduced the severity and duration of acute and fractionated radiation-induced oral mucositis and significantly reduced the duration of ulcerative mucositis in the chemoradiation model, with benefit dependent on both dose and schedule.
Personalized medicine for mucositis: Bayesian networks identify unique gene clusters which predict the response to gamma-D-glutamyl-L-tryptophan (SCV-07) for the attenuation of chemoradiation-induced oral mucositis Limited evidence
Identified 107 discriminating genes and a 10-gene cluster predictive of response, implicitly confirming that response to SCV-07 was heterogeneous across treated subjects.
The effect of thymogen on the state of immunity in destructive pulmonary tuberculosis Limited evidence
Reported stimulation of the T-cell compartment, improved tolerance of antituberculous chemotherapy, resolution of intoxication syndrome and healing of cavities.
Thymogen in the treatment of type-1 diabetes mellitus Limited evidence
Reported that thymogen removed signs of secondary immunodeficiency through activation of T-lymphocyte differentiation, with clinical effect in 94.4% and laboratory improvement in 83.3% of patients.
Safety
There is no modern adverse event database for thymogen. Russian clinical reports describe it as well tolerated, but without systematic adverse event ascertainment or independent monitoring those statements carry limited weight. Structurally, a dipeptide composed of two proteinogenic amino acids is a low-concern molecule on first principles, and no distinctive toxicity signal has been reported in the SCV-07 phase 2 programme either.
The practical risks lie elsewhere. Material sold online has no verified identity, and given the widespread conflation with SCV-07, there is a genuine possibility that a product labelled thymogen contains the γ-D isomer or a mixture. Injectable preparations sold outside pharmaceutical supply chains have no sterility or endotoxin testing. And an agent proposed to alter T-cell differentiation has never been evaluated in people with autoimmune disease, transplant recipients or those on immunosuppressive therapy. Absence of reported harm in a small, poorly monitored literature is not the same as demonstrated safety.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No MHRA marketing authorisation. Not a licensed medicine in the UK. |
| United States | Not approved by the FDA. The related compound SCV-07 (golotimod) held investigational status and reached phase 2 trials without approval; thymogen itself has no US regulatory status and is sold only under 'research use only' labelling. |
| WADA (sport) | Not named on the WADA Prohibited List. Athletes should nonetheless consider section S0 (unapproved substances), which captures pharmacological substances not approved by any governmental regulatory health authority for human therapeutic use, and should seek a formal ruling rather than assume permitted status. |
Questions
No, and this is the single most common error made about this compound. Thymogen is α-L-glutamyl-L-tryptophan. SCV-07 (golotimod) is γ-D-glutamyl-L-tryptophan. The amino acids are joined through a different carboxyl group and the glutamate has the opposite stereochemistry. They are distinct molecules with different stability and different development histories. The Western phase 2 trials in oral mucositis and hepatitis C used SCV-07, not thymogen, and their data cannot be attributed to thymogen.
One study is described as a double-blind randomised placebo-controlled trial: Smirnov and colleagues in 2011, examining preoperative thymogen in elderly patients undergoing abdominal tumour surgery, reporting fewer postoperative complications. It is published in Russian in a specialist gerontology journal and the sample size is not given in the accessible abstract, so the result cannot be independently appraised. There are no thymogen trials registered on ClinicalTrials.gov.
Thymogen is the synthetic version of one short peptide (Glu-Trp) that Khavinson's group identified as an active constituent within thymalin, the calf thymus extract. Thymalin is the undefined mixture; thymogen is one defined fragment of it. Two other constituents named by the same group are Lys-Glu (vilon) and Glu-Asp-Pro (crystagen).
It is a registered medicine in Russia and has been for decades. It has no FDA approval and no MHRA marketing authorisation, and has never been submitted for approval in the US, UK or EU. Product sold internationally reaches consumers through 'research use only' labelling, which permits sale of an unapproved compound without therapeutic claims. It is a legal shield, not a quality or evidence standard.